Health And Pharma
WEBHealth & Pharma. Health and Pharma is a new-generation international news and communication platform. Our goal is to collaborate with health science and pharma professionals to report directly from the news sources and strive to be recognized as a trusted news platform.
NETTER-2 Trial: Lutathera Cuts Risk of Death by 72% in …
WEBJan 19, 2024 · The trial focused on the efficacy of Lutathera® (lutetium (177Lu) oxodotreotide / USAN: lutetium Lu 177 dotatate) in combination with long-acting release (LAR) octreotide, marking a significant stride in first-line treatments for this cancer type.One of the key metrics in the trial was the progression-free survival (PFS). Patients treated with Lutathera® and octreotide LAR experienced a ...
First Lung Cancer Vaccine Trial for BioNTech's BNT116 Launched …
WEB25 August 2024. The first human trial of BNT116, an mRNA-based lung cancer vaccine, has started, and the first patient received the treatment at UCLH. Developed by BioNTech, the vaccine targets non-small cell lung cancer (NSCLC) by enhancing the immune response to cancer cells. Spanning seven countries, the global trial aims to evaluate the ...
FDA Grants IND Approval to RemeGen's RC88 for Phase II Ovarian …
WEBFDA & EMA. 2 January 2024. RemeGen's RC88, a novel drug targeting mesothelin, received FDA approval for Phase II trials in treating platinum-resistant recurrent ovarian cancer. This antibody-drug conjugate offers a targeted approach against a form of cancer with limited treatment options. RemeGen has announced that its independently developed ...
AI-Powered Treatment Success: LP-300 Shows Promise for Non …
WEBONCOLife / 12 August 2024. The Phase 2 HARMONIC™ trial, leveraging the AI-assisted RADR® platform, demonstrates promising outcomes for LP-300 in treating non-smoker lung cancer patients, with an 86% clinical benefit rate. This novel therapy targets unique genetic mutations, offering new hope for a globally expanding patient demographic.
A New Era in Oncology: Programmable mRNA Therapies in the …
WEBApr 4, 2024 · Strand Therapeutics promises a new class of cancer treatment with its programmable mRNA therapies designed to precisely target cancer cells. With FDA clearance for a Phase 1 trial of their lead therapy, STX-001, they aim to improve solid tumor treatment outcomes and advance personalized medicine. Strand Therapeutics, an enterprise born from the ...
Bayer's New Lung Cancer Drug Receives Critical FDA Breakthrough …
WEB1 March 2024. Bayer announced that its investigational drug BAY 2927088 has been awarded the Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA). This promising development brings new hope to patients battling non-small cell lung cancer (NSCLC) with specific HER2 activating mutations, offering a potential new avenue ...
Iptacopan, the First CI, Wins FDA Accelerated Approval for IgA …
WEB8 August 2024. The FDA has granted accelerated approval to Fabhalta® (iptacopan) for reducing proteinuria in IgA nephropathy (IgAN) patients. Developed by Novartis, this first-in-class complement inhibitor demonstrated a 44% reduction in proteinuria in trials, marking a significant advancement in treatment options for this rare kidney disease.
Boehringer Ingelheim's P-II Trial Sparks Hope for Chronic Kidney ...
WEB4 November 2023. A groundbreaking Phase II trial by Boehringer Ingelheim shows its novel aldosterone synthase inhibitor BI 690517, on top of empagliflozin, significantly reduces albuminuria in CKD patients by up to 39.5%. The results of the trial, presented at the American Society of Nephrology's Kidney Week 2023, promise a new treatment ...
Posts | Health And Medicine
WEBHealth & Pharma. Health and Pharma is a new-generation international news and communication platform. Our goal is to collaborate with health science and pharma professionals to report directly from the news sources and strive to be recognized as a trusted news platform.